Literature DB >> 11830470

Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.

Zhong Q Li1, Weiyi Liu, Kwang S Park, Brue S Sachais, Gowthani M Arepally, Douglas B Cines, Mortimer Poncz.   

Abstract

Heparin-induced thrombocytopenia/thrombosis (HIT/T) is a common complication of heparin therapy that is caused by antibodies to platelet factor 4 (PF4) complexed with heparin. The immune response is polyclonal and polyspecific, ie, more than one neoepitope on PF4 is recognized by HIT/T antibodies. One such epitope has been previously identified; it involves the domain between the third and fourth cysteine residues in PF4 (site 1). However, the binding sites for other HIT/T antibodies remain to be defined. To explore this issue, the binding site of KKO, an HIT/T-like murine monoclonal antibody, was defined. KKO shares a binding site with many HIT/T antibodies on PF4/heparin, but does not bind to site 1 or recognize mouse PF4/heparin. Therefore, the binding of KKO to a series of mouse/human PF4 chimeras complexed with heparin was examined. KKO recognizes a site that requires both the N terminus of PF4 and Pro34, which immediately precedes the third cysteine. Both regions lie on the surface of the PF4 tetramer in sufficient proximity (within 0.74 nm) to form a contiguous antigenic determinant. The 10 of 14 HIT/T sera that require the N terminus of PF4 for antigen recognition also require Pro34 to bind. This epitope, termed site 2, lies adjacent to site 1 in the crystal structure of the PF4 tetramer. Yet sites 1 and 2 can be recognized by distinct populations of antibodies. These studies further help to define a portion of the PF4 tetramer to which self-reactive antibodies develop in patients exposed to heparin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830470     DOI: 10.1182/blood.v99.4.1230

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

2.  PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.

Authors:  Raj S Kasthuri; Sam L Glover; William Jonas; Troy McEachron; Rafal Pawlinski; Gowthami M Arepally; Nigel S Key; Nigel Mackman
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

3.  PF4/heparin complexes are T cell-dependent antigens.

Authors:  Shayela Suvarna; Lubica Rauova; Emily K E McCracken; Christina M Goss; Bruce S Sachais; Steven E McKenzie; Michael P Reilly; Michael Dee Gunn; Douglas B Cines; Mortimer Poncz; Gowthami Arepally
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

Review 4.  Heparin-induced thrombocytopenia: present and future.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

5.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

Review 6.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

7.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

8.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

9.  Optimization of a murine immunization model for study of PF4/heparin antibodies.

Authors:  S Suvarna; R Qi; G M Arepally
Journal:  J Thromb Haemost       Date:  2009-02-24       Impact factor: 5.824

Review 10.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.